CCNK and melanoma: This effect was not specific to a particular cell line, as we found that SR-4835 treatment (2 h) of three additional BRAF-mutated (V600E) melanoma cell lines (WM164, WM983B and COLO829) also resulted in reduced cyclin K levels (Fig. 2B).